https://nl.marketscreener.com/koers/aandeel/REMEGEN-CO-LTD-119080101/nieuws/RemeGen-Co-kondigt-de-resultaten-aan-van-de-Fase-III-studie-met-telitacicept-voor-de-behandeling-va-44669788/?utm_source=telegram&utm_medium=social&utm_campaign=share